Abstract
The sentinel node biopsy (SLNB) plays since its introduction in 1992 an indisputable role in the management of melanomas thicker than 1 mm. Its indication is instead debated for "thin" melanomas, with Breslow thickness less than 1 mm (T1), due to the lack of a reliable distinction between melanomas T1a (theoretically at low risk of lymph node metastasis) and T1b melanomas (at higher risk and with indication of sentinel lymph node). From 2001 to date, AJCC has released 3 different staging systems that have identified T1b melanomas with radically different criteria (2001: T1b if Clark higher than or equal to 4; 2009: T1b if mitosis presence; 2017: T1b if Breslow is greater than or equal to 0,8 mm). The presence of ulceration is the only common parameter that identifies T1b stages in all the 3 classification.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
